Gilead Sciences reported $1000K in Ordinary Share Capital for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ordinary Share Capital Change
Agios Pharmaceuticals AGIO:US USD 71K 0
Alnylam Pharmaceuticals ALNY:US USD 1.24M 10K
Biogen BIIB:US USD 100K 0
Biomarin Pharmaceutical BMRN:US USD 186K 0
Bluebird Bio BLUE:US USD 829K 94K
Coherus Biosciences CHRS:US USD 8K 1000
GlaxoSmithKline GSK:LN GBP 1.35B 0
Glaxosmithkline GSK:US GBP 1.35B 0
Intercept Pharmaceuticals ICPT:US USD 42K 1000
Moderna Inc MRNA:US USD 38.5K 200
Neurocrine Biosciences NBIX:US USD 100K 0
Novartis NOVN:VX USD 890M 0
Ptc Therapeutics PTCT:US USD 72K 1000
Puma Biotechnology PBYI:US USD 5K 0
Sangamo Biosciences SGMO:US USD 1.67M 49K
Sarepta Therapeutics SRPT:US USD 9K 0
Teva Pharmaceutical Industries TEVA:US USD 57M 0
United Therapeutics UTHR:US USD 700K 0